One strategy for treating cancer while limiting off-target effects on healthy cells is to conjugate cytotoxic agents to small-molecule ligands for receptors that are upregulated in tumours. Low and colleagues explain the key aspects to be considered when designing ligand–drug conjugates, and summarize the ligand–drug and ligand–imaging agent conjugates that are currently in clinical trials.
- Madduri Srinivasarao
- Chris V. Galliford
- Philip S. Low
